Results 161 to 170 of about 49,422 (318)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Molecular detection and identification of relapsing fever Borrelia in ticks and wild small mammals in China. [PDF]

Emerg Microbes Infect, 2022
Zhang XA, Tian F, Li Y, Zhang XL, Jiang BG, Liu BC, Zhang JT, Tian S, Ding H, Li S, Li H, Fang LQ, Liu W.   +12 more
europepmc   +1 more source

The return of metabolism: biochemistry and physiology of glycolysis

Biological Reviews, EarlyView.
ABSTRACT Glycolysis is a fundamental metabolic pathway central to the bioenergetics and physiology of virtually all living organisms. In this comprehensive review, we explore the intricate biochemical principles and evolutionary origins of glycolytic pathways, from the classical Embden–Meyerhof–Parnas (EMP) pathway in humans to various prokaryotic and ...
Nana‐Maria Grüning, Federica Agostini, Camila Caldana, Johannes Hartl, Matthias Heinemann, Markus A. Keller, Jan Lukas Krüsemann, Costanza Lamperti, Carole L. Linster, Steffen N. Lindner, Julia Muenzner, Jens Nielsen, Zoran Nikoloski, Bettina Siebers, Jacky L. Snoep, Hezi Tenenboim, Bas Teusink, Spencer J. Williams, Mirjam M. C. Wamelink, Markus Ralser   +19 more
wiley   +1 more source

Relapsing fever borrelioses: forgotten and new ones

Терапевтический архив, 2010
Relapsing fever borrelioses are widely spread in the endemic regions of Eurasia, Africa, and America as before and account for significant morbidity and mortality; however, these infections have been recently underestimated.
Aleksandr Evgen'evich Platonov, Viktor Vasil'evich Maleev, Lyudmila Stanislavovna Karan', A E Platonov, V V Maleyev, L S Karan   +5 more
doaj  

Epistaxis and thrombocytopenia as major presentations of louse borne relapsing fever: Hospital-based study. [PDF]

PLoS One, 2022
Abera EG, Tukeni KN, Didu GH, Chala TK, Yilma D, Gudina EK.   +5 more
europepmc   +1 more source

Tick-Borne Relapsing Fever Caused by Borrelia persica in Traveler to Central Asia, 2019 [PDF]

, 2020
Veronika Muigg, Helena M. B. Seth-Smith, Daniel Goldenberger, Adrian Egli, Beatrice Nickel, Roland Dürig, Esther Kuenzli, Vladimira Hinić, Andreas Neumayr   +8 more
openalex   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

Tick-Borne Relapsing Fever Caused by Borrelia persica in Traveler to Central Asia, 2019

, 2020
Veronika Muigg, Helena M. B. Seth-Smith, Daniel Goldenberger, Adrian Egli, Beatrice Nickel, Roland Dürig, Esther Kuenzli, Vladimira Hinić, Andreas Neumayr   +8 more
openalex   +2 more sources

The Resolution of Relapsing Fever Borreliosis Requires IgM and Is Concurrent with Expansion of B1b Lymphocytes [PDF]

, 2003
Kishore R. Alugupalli, Rachel M. Gerstein, Jianzhu Chen, Eva Szomolanyi‐Tsuda, Robert T. Woodland, John M. Leong   +5 more
openalex   +1 more source

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan

Cancer Science, EarlyView.
The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada, Akiko M. Saito, Kei Fukuhara, Masahiro Sekimizu   +12 more
wiley   +1 more source